◆ TICKERBASE · US STOCK FINANCIAL DATA LIBRARY

HomeAll stocks › MENS

Jyong Biotech Ltd. (MENS) Financial History

4 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

Healthcare · Biotechnology · DATA UPDATED 2026-07-09

Jyong Biotech Ltd. (MENS) operates in the Biotechnology industry and is headquartered in New Taipei City, Taiwan with about 27 employees. Its market capitalization is roughly $174 million. In the fiscal year ended 2025-12-31, MENS reported $0M in revenue and ($5M) in net income.

Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia.

Interactive charts & full statements →

MENS Revenue & Earnings History — Annual Income Statement

Income statement2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Revenue$0M$0M$0M$0M
Operating Income (EBIT)($3M)($2M)($3M)($3M)
Net Income($5M)($3M)($4M)($7M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

MENS Free Cash Flow History

MENS Balance Sheet History

Balance sheet2025-12-312024-12-312023-12-312022-12-312021-12-31
Total Assets$21M$6M$8M$9M
Total Liabilities$46M$43M$42M$38M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MENS viewer.

Other Companies in Biotechnology

← MELIAll stocksMEOH →

About TickerBase · Data methodology & sources

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.